– ISRAEL – Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today that it has appointed Steve Dubin as Chairman of its board of directors, effective January 1, 2014.
The Company also announced that Yoav Doppelt has been appointed as Vice Chairman of the board. Mr. Doppelt has served as Chairman of Enzymotec’s board of directors since October 2011 and as a director since 2001. He will continue to be an actively involved board member and will assist Mr. Dubin during the transition process.
Yoav Doppelt commented, “We are very pleased that Mr. Dubin has agreed to lead our board. His intellect, depth of business knowledge and proven leadership skills have already made many valuable contributions since he joined Enzymotec’s board, and we look forward to his further assistance in augmenting our growth strategies. We believe that his wealth of nutritional expertise will both support our commitment to providing our customers with the highest quality products and to enhancing the market leadership of Enzymotec.”
Steve Dubin said, “Enzymotec’s industry reputation, solid product portfolio and focus on innovation position the Company as a recognized global leader in the large and growing nutritional markets. I am grateful to the board of directors for the opportunity, and I am excited to work further with the talented and dedicated Enzymotec team.”
Steve Dubin has served as Vice Chairman of Enzymotec’s board of directors since April 2013. Since November 2011, Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health and wellness and nutritional products markets, on matters including corporate development, business acquisitions, customer relations, growth strategies and corporate finance. Mr. Dubin also acts as a Senior Advisor to Paine & Partners, LLC, a global private equity investment firm, helping to identify and to execute investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011, Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He also served as President of DSM’s Nutritional Lipids Division immediately after DSM’s acquisition of Martek and as a Senior Advisor to DSM Nutritional Products from 2011 through October 2012. Having joined Martek in 1992, he held various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, as well as President of Martek from 2003 to 2006. Mr. Dubin is a co-founder and co-manager of a Maryland-based, angel-investing club. Mr. Dubin currently serves as a member of the board of several privately held companies, including The Brain Center, LLC, MyCell Technologies and its subsidiary Oceans Omega LLC, and Alcresta, Inc. Prior to that, he was a member of the board of directors of Scerene Healthcare, Inc. Mr. Dubin holds a bachelor’s degree in accounting from the University of Maryland and a Juris Doctor degree from the National Law Center at George Washington University. He is a certified public accountant and a member of the Maryland Bar.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.